JO
IKT icon

John Overdeck’s Inhibikase Therapeutics IKT Stock Holding History

John Overdeck’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Sell
806,264
-41,347
-5% -$74K ﹤0.01% 3176
2026
Q1 		$1.42M Buy
+847,611
New +$1.51M ﹤0.01% 3006
2022
Q1 		– Sell
-1,917
Closed -$17K – 3429
2021
Q4 		$17K Buy
+1,917
New +$21.2K ﹤0.01% 4178

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

John Overdeck's IKT Position: Q2 2026 in Review

John Overdeck reduced its Inhibikase Therapeutics (IKT) stake by 4.9% in Q2 2026, selling an estimated $74K and leaving 806,264 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3176.

John Overdeck first reported a position in IKT in Q4 2021 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • John Overdeck held 806,264 shares of Inhibikase Therapeutics worth $1.64M as of Q2 2026.
  • John Overdeck sold 41,347 Inhibikase Therapeutics shares in Q2 2026, an estimated $74K.
  • Inhibikase Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3176 holding.
  • John Overdeck first reported a position in Inhibikase Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.